In the past week, AMIX stock has gone down by -15.27%, with a monthly decline of -23.92% and a quarterly plunge of -43.40%. The volatility ratio for the week is 2.86%, and the volatility levels for the last 30 days are 4.05% for Autonomix Medical Inc The simple moving average for the past 20 days is -18.61% for AMIX’s stock, with a -76.32% simple moving average for the past 200 days.
Is It Worth Investing in Autonomix Medical Inc (NASDAQ: AMIX) Right Now?
The stock has a 36-month beta value of -3.47. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AMIX is 2.19M, and at present, short sellers hold a 5.21% of that float. On June 05, 2025, the average trading volume of AMIX was 131.80K shares.
AMIX) stock’s latest price update
The stock price of Autonomix Medical Inc (NASDAQ: AMIX) has dropped by -13.72 compared to previous close of 1.64. Despite this, the company has seen a fall of -15.27% in its stock price over the last five trading days. globenewswire.com reported 2025-06-05 that Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix’s strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received Ethics Committee authorization from the Ministry of Health of the Republic of Uzbekistan to open the clinical trial site for the follow-on phase to its proof-of-concept human clinical trial (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. The Company is on track to commence enrollment in June 2025.
AMIX Trading at -22.18% from the 50-Day Moving Average
After a stumble in the market that brought AMIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.66% of loss for the given period.
#####
#####
Stock Fundamentals for AMIX
The total capital return value is set at -1.11. Equity return is now at value -145.09, with -118.76 for asset returns.
Based on Autonomix Medical Inc (AMIX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -7.1. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -61.44.
Currently, EBITDA for the company is -15.27 million with net debt to EBITDA at 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.63.
Conclusion
To sum up, Autonomix Medical Inc (AMIX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
